Roelof Willemze, Stefan Suciu, Giovanna Meloni, Boris Labar, Jean-Pierre Marie, Constantijn J M Halkes, Petra Muus, Martin Mistrik, Sergio Amadori, Giorgina Specchia, Francesco Fabbiano, Francesco Nobile, Marco Sborgia, Andrea Camera, Dominik L D Selleslag, Francois Lefrère, Domenico Magro, Simona Sica, Nicola Cantore, Meral Beksac, Zwi Berneman, Xavier Thomas, Lorella Melillo, Jose E Guimaraes, Pietro Leoni, Mario Luppi, Maria E Mitra, Dominique Bron, Georges Fillet, Erik W A Marijt, Adriano Venditti, Anne Hagemeijer, Marco Mancini, Joop Jansen, Daniela Cilloni, Liv Meert, Paola Fazi, Marco Vignetti, Silvia M Trisolini, Franco Mandelli, Theo de Witte
PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment containing daunorubicin, etoposide, and either standard-dose (SD) cytarabine (100 mg/m(2) per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m(2) every 12 hours by 3-hour infusion on days 1, 3, 5, and 7)...
January 20, 2014: Journal of Clinical Oncology